Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Completed 3

Sponsor Class

OTHER 6NIH 3INDUSTRY 3

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Head & Neck 3

Conditions

Differentiated Thyroid Cancer 4Thyroid Neoplasms 3Thyroid Cancer, Papillary 1Adenocarcinoma, Follicular 1

Interventions

lenvatinib 9vandetanib 5pembrolizumab 4Sorafenib 4selpercatinib 3Thyrotropin Alfa 3trametinib 2fosbretabulin 2combretastatin 2cabozantinib 2belinostat 2Paclitaxel 2Gemcitabine 2Fluorouracil 2Cetuximab 2Carboplatin 2Axitinib 2130-nm albumin-bound paclitaxel 2ulixertinib 1trastuzumab deruxtecan 1tipifarnib 1surufatinib 1repotrectinib 1pralsetinib 1naporafenib 1motesanib diphosphate 1methyl N-acetylsibirosaminide 1larotrectinib 1irofulven 1durvalumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Thyroid Neoplasms × Thyrotropin Alfa × Clear all
NCT03276988 2020-09-09

Tolerability, Safety and Pharmacokinetics Study of GX-30 in Total Thyroidectomy or Near Total Thyroidectomy Patients

Genexine, Inc.

Phase 1/2 Completed
8 enrolled
Head & Neck

Thyroid Neoplasms

NCT01736163 2015-03-23

A Retrospective Observational Study Comparing Two Different Treatment Options in Thyroid Cancer Patients With T4 Tumours

Sanofi

Completed
144 enrolled
Head & Neck

Thyroid Neoplasms

NCT00196729 2015-03-18

Comparison of the Safety and Successful Ablation of Thyroid Remnant in Post-thyroidectomized Euthyroid Patients (i.e. Patients Administered Thyrogen) Versus Hypothyroid Patients (no Thyrogen) Following 131I Administration

Sanofi

Phase 3 Completed
63 enrolled
Head & Neck

Thyroid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡